deepCDR Biologics is a cutting-edge biotechnology startup that specializes in antibody discovery using advanced Deep Learning techniques. The company combines these methods with its proprietary mammalian display process to sift through a vast array of antibodies. This allows them to quickly identify candidates that have the highest potential for effectiveness and ease of development. Essentially, deepCDR helps other biotech firms and pharmaceutical companies find the best antibodies for therapeutic, prophylactic (preventive), and diagnostic purposes.

The primary market deepCDR operates in is the biotechnology and pharmaceutical sector, particularly focusing on companies involved in developing treatments and diagnostics for diseases, including the ongoing efforts against SARS-CoV-2 (the virus causing COVID-19). Their clients are typically other biotech firms, pharmaceutical companies, and research institutions that need to identify and develop high-affinity antibodies quickly.

deepCDR's business model revolves around providing specialized antibody engineering services. They make money by partnering with these companies and offering their expertise in rapidly bringing antibody leads into preclinical and clinical studies. They also provide patient repertoire analysis, which involves examining the variety of antibodies present in patients, using their proprietary deep sequencing and deep learning methods.

In summary, deepCDR Biologics leverages advanced technology to accelerate the discovery and development of high-quality antibodies, serving a critical need in the biotech and pharmaceutical industries.

Keywords: Antibody Discovery, Deep Learning, Biotechnology, Pharmaceutical, SARS-CoV-2, Therapeutics, Diagnostics, Mammalian Display, Preclinical Studies, Patient Repertoire Analysis.